Medicus Pharma Inks Pfizer Co-Development Deal for CD228V ADC — $27M Upfront, $1B+ Milestones
MDCX is trading near its 52-week low of $0.243 (13% above the low) on light trading volume (0.2× avg).
Summary
Medicus Pharma licensed Pfizer's CD228V ADC in a co-development deal requiring $27M in upfront payments over 12 months, with $1B+ in potential milestones and low double-digit royalties owed to Pfizer.
Key Events · M&A and Partnerships · MDCX
-
Pfizer Co-Development Agreement Signed
On September 2, 2026, Medicus Pharma Inc. entered into a Co-Development and License Agreement with Pfizer Inc. for exclusive worldwide rights to CD228V (PF-08046031), an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228).
-
$27M Upfront Obligation vs $2M Funding
Medicus paid Pfizer $12.0M on the effective date and owes an additional $15.0M on the first anniversary. Simultaneously, Pfizer paid Medicus a one-time $2.0M Development Funding Payment restricted to CD228V development activities.
-
$1B+ Milestone and Royalty Economics
Pfizer is eligible for development, regulatory, and sales milestone payments exceeding $1.0 billion in aggregate, plus tiered low double-digit royalties on annual net sales, on a product-by-product and country-by-country basis.
-
Liquidity Risk Against Going Concern
The $27M total upfront commitment is nearly double the $15.2M cash balance reported in the August 12, 2026 10-Q, which reiterated going concern doubts. The company has been funding operations through a highly dilutive ATM program.
Analysis · MDCX · Life Sciences
A transformative bet for a micro-cap with $15.2M in cash and a going-concern warning: Medicus Pharma has secured a worldwide license from Pfizer for CD228V, an early clinical-stage antibody-drug conjugate. The deal requires $27M in upfront payments to Pfizer over the next year — nearly double the company's current cash balance — while Pfizer contributes only $2M in development funding. In exchange, Medicus gains a Pfizer-validated oncology asset and a path to $1B+ in milestone economics, but the near-term cash obligation is severe for a company already facing Nasdaq delisting and heavy ATM dilution. The market will weigh pipeline upside against immediate liquidity risk.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDCX was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.24 to $3.05. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.